Firstly both crestor and Lipitor patients are both combined in the BOM trial for time to first occurrence. So that procedure has to take place for that purpose to determine the top line results and as we know now that failed.

Secondly the reason why you need both crestor and Lipitor in the mix so  had  thaB succeeded apabetalone be made available for all cardiovascular diseased patients whether they take crestor or Lipitor to capture the overall market.

Koo